| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Khasianine does not have a single defined pharmacological target. As a steroidal glycoside and alkaloid, it likely interacts with multiple cellular targets to exert its diverse biological activities. The compound exhibits anti-tumor activity and reduces the proliferation of LNCaP prostate and T47D breast cancer cells. It also shows strong activity against CCl4-induced liver damage, suggesting hepatoprotective effects. The rhamnose moiety of related compounds plays a crucial role in triggering cell death by apoptosis, indicating that the sugar moiety of Khasianine may be important for its biological activity.
|
|---|---|
| ln Vitro |
Khasianine exhibits strong activity against liver damage induced by CCl4. It reduces the proliferation of LNCaP prostate and T47D breast cancer cells with IC50s of 32.1 and 27.5 µM, respectively. The compound has anti-tumor activity. The rhamnose moiety of solamargine, a related compound, plays a crucial role in triggering cell death by apoptosis, suggesting that the sugar moiety of Khasianine may be important for its apoptotic effects. The compound's diverse biological activities make it a valuable lead compound for drug discovery.
|
| ln Vivo |
No specific in vivo activity data is publicly available for Khasianine. The compound exhibits strong activity against liver damage induced by CCl4, suggesting potential hepatoprotective effects in vivo. It has anti-tumor activity, indicating potential efficacy in cancer models. However, specific in vivo studies with Khasianine have not been detailed in the available literature. The compound is primarily studied in the context of medicinal plant research and as a lead structure for drug discovery.
|
| Enzyme Assay |
No specific non-cell assay protocol is available for Khasianine. As a natural product with multiple activities, it could be evaluated in various cell-free assays depending on the specific activity being studied. For anti-tumor activity, enzyme inhibition assays or receptor binding assays could be employed. For hepatoprotective activity, antioxidant assays such as DPPH radical scavenging or lipid peroxidation inhibition could be used. However, specific protocols have not been detailed in the available literature.
|
| Cell Assay |
No specific cell-based assay protocol is available for Khasianine. For anti-tumor activity, standard cell-based assays involve treatment of cancer cell lines (e.g., LNCaP prostate and T47D breast cancer cells) with Khasianine for 48-72 hours. Cell viability is measured using MTT or CellTiter-Glo assays to determine IC50 values. Apoptosis can be assessed by Annexin V/PI staining or caspase activity assays. For hepatoprotective activity, liver cell lines (e.g., HepG2) could be treated with CCl4 in the presence or absence of Khasianine, and cell viability and markers of liver damage would be measured.
|
| Animal Protocol |
No specific animal protocol is available for Khasianine. For hepatoprotective studies, standard in vivo models use CCl4-induced liver damage in rodents. Khasianine is administered (route and dose to be determined) prior to or following CCl4 treatment. Liver function markers (ALT, AST), histology, and oxidative stress markers are assessed. For anti-tumor studies, xenograft models using cancer cell lines could be employed. The compound's effects on tumor growth and survival would be evaluated.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data is available for Khasianine. The compound has a molecular weight of 721.92 and formula C39H63NO11. As a large steroidal glycoside, it would likely have limited oral bioavailability and may require parenteral administration. The compound is soluble in DMSO and other organic solvents. Comprehensive pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
No toxicology data is available for Khasianine. As a natural product, it would require comprehensive toxicological evaluation for therapeutic development. The compound's diverse biological activities suggest potential for both beneficial and adverse effects. Standard preclinical safety studies would be needed, including genotoxicity, hERG cardiac safety, and repeated-dose toxicity assessments. The compound is for research use only.
|
| References | |
| Additional Infomation |
Khasianine has the molecular formula C39H63NO11 and molecular weight 721.92. It is also known as β2-Solamargine. The compound is a steroidal glycoside and steroid sugar alkaloid found in Solanum nigrum L and other plants. It exhibits strong activity against CCl4-induced liver damage and has anti-tumor activity. It reduces the proliferation of LNCaP prostate and T47D breast cancer cells with IC50s of 32.1 and 27.5 µM, respectively. No clinical trial status has been identified; it is used in medicinal plant research and as a lead structure for drug discovery.
|
| Molecular Formula |
C39H63NO11
|
|---|---|
| Molecular Weight |
721.92
|
| Exact Mass |
721.44
|
| CAS # |
32449-98-2
|
| PubChem CID |
3479482
|
| Appearance |
White to off-white solid powder
|
| Density |
1.33g/cm3
|
| Boiling Point |
847.4ºC at 760mmHg
|
| Melting Point |
243 - 248 °C
|
| Flash Point |
466.3ºC
|
| Index of Refraction |
1.611
|
| LogP |
2.291
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
51
|
| Complexity |
1320
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KRQDMAXNTWLTDZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C39H63NO11/c1-18-8-13-39(40-16-18)19(2)28-26(51-39)15-25-23-7-6-21-14-22(9-11-37(21,4)24(23)10-12-38(25,28)5)48-36-33(46)31(44)34(27(17-41)49-36)50-35-32(45)30(43)29(42)20(3)47-35/h6,18-20,22-36,40-46H,7-17H2,1-5H3
|
| Chemical Name |
2-[4,5-dihydroxy-2-(hydroxymethyl)-6-(5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-piperidine]-16-yl)oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| Synonyms |
NSC-376459; NSC 376459; Khasianine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~69.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3852 mL | 6.9260 mL | 13.8520 mL | |
| 5 mM | 0.2770 mL | 1.3852 mL | 2.7704 mL | |
| 10 mM | 0.1385 mL | 0.6926 mL | 1.3852 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
